How to buy Pacira BioSciences stock

Pacira BioSciences, Inc is a drug manufacturers-specialty & generic business based in the US. Pacira BioSciences shares (PCRX) are listed on the NASDAQ and all prices are listed in US Dollars. Pacira BioSciences employs 606 staff and has a trailing 12-month revenue of around USD$421.1 million.

How to buy shares in Pacira BioSciences

1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
3. Search for Pacira BioSciences. Find the stock by name or ticker symbol: PCRX. Research its history to confirm it's a solid investment against your financial goals.
4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Pacira BioSciences reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
5. Decide on how many to buy. Weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Pacira BioSciences, depending on your broker.
6. Check in on your investment. Congratulations, you own a part of Pacira BioSciences. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

Pacira BioSciences share price

Use our graph to track the performance of PCRX stocks over time.

Pacira BioSciences shares at a glance

• Key figures

Information last updated 2021-02-23.

52-week range	USD$27.46 - USD$79.98
50-day moving average	USD$71.4709
200-day moving average	USD$62.2945
Wall St. target price	USD$74.15
PE ratio	25.5203
Dividend yield	N/A (0%)
Earnings per share (TTM)	USD$2.931

Buy Pacira BioSciences shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

*Signup bonus information updated weekly.

Is it a good time to buy Pacira BioSciences stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Technical Analysis of Pacira BioSciences, Inc by TradingView

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Pacira BioSciences financials

Revenue TTM	USD$421.1 million
Operating margin TTM	9.65%
Gross profit TTM	USD$242.2 million
Return on assets TTM	2.51%
Return on equity TTM	27.1%
Profit margin	29.95%
Book value	$13.499
Market capitalisation	USD$3.2 billion

TTM: trailing 12 months

Shorting Pacira BioSciences shares

There are currently 6.2 million Pacira BioSciences shares held short by investors – that's known as Pacira BioSciences's "short interest". This figure is 5.3% down from 6.6 million last month.

There are a few different ways that this level of interest in shorting Pacira BioSciences shares can be evaluated.

Pacira BioSciences's "short interest ratio" (SIR)

Pacira BioSciences's "short interest ratio" (SIR) is the quantity of Pacira BioSciences shares currently shorted divided by the average quantity of Pacira BioSciences shares traded daily (recently around 589652.27272727). Pacira BioSciences's SIR currently stands at 10.56. In other words for every 100,000 Pacira BioSciences shares traded daily on the market, roughly 10560 shares are currently held short.

However Pacira BioSciences's short interest can also be evaluated against the total number of Pacira BioSciences shares, or, against the total number of tradable Pacira BioSciences shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Pacira BioSciences's short interest could be expressed as 0.14% of the outstanding shares (for every 100,000 Pacira BioSciences shares in existence, roughly 140 shares are currently held short) or 0.2014% of the tradable shares (for every 100,000 tradable Pacira BioSciences shares, roughly 201 shares are currently held short).

A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against Pacira BioSciences.

Find out more about how you can short Pacira BioSciences stock.

Pacira BioSciences share price volatility

Over the last 12 months, Pacira BioSciences's shares have ranged in value from as little as $27.46 up to $79.98. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Pacira BioSciences's is 1.1345. This would suggest that Pacira BioSciences's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).

Pacira BioSciences overview

Pacira BioSciences, Inc. provides non-opioid pain management and regenerative health solutions for health care practitioners and their patients in the United States. The company develops products based on its proprietary DepoFoam product delivery technology that encapsulates drugs without altering their molecular structure. It offers EXPAREL, a non-opioid medication administered at the time of surgery to control pain while reducing opioid requirements; and iovera system, a handheld cryoanalgesia device used to deliver controlled doses of cold temperature only to targeted nerves. The company has collaboration with Aetna. The company was formerly known as Pacira Pharmaceuticals, Inc. and changed its name to Pacira BioSciences, Inc. in April 2019. Pacira BioSciences, Inc. was founded in 2006 and is headquartered in Parsippany, New Jersey.

Frequently asked questions

• What percentage of Pacira BioSciences is owned by insiders or institutions?

  Currently 0.799% of Pacira BioSciences shares are held by insiders and 116.41% by institutions.

• How many people work for Pacira BioSciences?

  Latest data suggests 606 work at Pacira BioSciences.

• When does the fiscal year end for Pacira BioSciences?

  Pacira BioSciences's fiscal year ends in December.

• Where is Pacira BioSciences based?

  Pacira BioSciences's address is: 5 Sylvan Way, Parsippany, NJ, United States, 07054

• What is Pacira BioSciences's ISIN number?

  Pacira BioSciences's international securities identification number is: US6951271005

• What is Pacira BioSciences's CUSIP number?

  Pacira BioSciences's Committee on Uniform Securities Identification Procedures number is: 695127100